Traumatic spinal cord injury

By Christopher S Ahuja, Jefferson R. Wilson, Satoshi Nori, M. Kotter, C. Druschel, A. Curt, M. Fehlings. Nature Reviews Disease Primers, 2017

1,580 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

NF-κB in biology and targeted therapy: new insights and translational implications (2024, background): “469 It has been implicated as a critical determinant of cell death and central nervous system diseases.”
Hallmarks of neurodegenerative diseases. (2023, neutral): “Such non-proteinopathic diseases include TBI, 32,33 CTE, 32,33 stroke, 34,35 SCI, 36 and MS, 37,38 where the primary insult is not obviously related to protein aggregation.”
Clinical applications of stem cell-derived exosomes (2024, background): “92 Despite surgical intervention, clinical studies involving pharma-cotherapy can be broadly classi ﬁ ed as either neuroprotective or neuroregenerative.”
Spinal cord injury: molecular mechanisms and therapeutic interventions (2023, background): “Riluzole is known as a neuroprotective agent.(5) As a sodium channel blocker, Riluzole blocks the sodium channels and prevents the excessive influx of sodium ions, reduces the intracellular sodium concentration and influx of calcium ions which cause the development of intracellular acidosis and cyto”